TRVI

Trevi Therapeutics, Inc. [TRVI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TRVI Stock Summary

Top 10 Correlated Stocks

TRVI


In the News

10:49 29 Sep 2023 TRVI

Trevi Therapeutics, Inc. (TRVI) Q2 2023 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham and Company Leland Gershell - Oppenheimer William Wood - B. Riley Securities Operator Good afternoon and welcome to the Trevi Therapeutics' Second Quarter 2023 Earnings Conference Call.

11:10 29 Sep 2023 TRVI

Trevi Therapeutics, Inc. (TRVI) Q4 2022 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Jennifer Good - President & Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Leland Gershell - Oppenheimer Nat Charoensook - SVB Securities Sean Kim - Jones Trading Mayank Mamtani - B. Riley Securities Operator Good afternoon and welcome to the Trevi Therapeutics Q4 and Year-End 2022 Earnings Conference Call.

07:30 29 Sep 2023 TRVI

Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023

Corporate presentation at 10:50 a.m. ET NEW HAVEN, Conn.

07:41 29 Sep 2023 TRVI

Trevi Therapeutics, Inc. (TRVI) Q3 2022 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - CFO Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham & Company Operator Good afternoon, and welcome to the Trevi Therapeutics Q3 2022 Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded.

04:48 29 Sep 2023 TRVI

Andreas Halvorsen Enters Holding in Trevi Therapeutics

Andreas Halvorsen (Trades, Portfolio), a founding partner of Viking Global Investors LP, revealed in a Schedule 13G filing that he entered a new position in Trevi Therapeutics Inc. ( TRVI , Financial).

08:22 29 Sep 2023 TRVI

These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)

Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).

08:20 29 Sep 2023 TRVI

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2022 Results - Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants Annabel Samimy – Stifel Serge Belanger – Needham & Company Leland Gershell – Oppenheimer Nathan Weinstein – Aegis Operator Good afternoon, and welcome to the Trevi Therapeutics Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

07:30 29 Sep 2023 TRVI

Trevi Therapeutics to Present at Upcoming August Conferences

NEW HAVEN, Conn. , Aug. 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced it will be presenting at the following investor and medical meeting conferences: Senior management at Trevi Therapeutics will be presenting at August investor and medical meeting conferences Stifel Biotech Executive Summer Summit (In-person) Date: Tuesday, August 16, 2022 Fireside chat presentation: Jennifer Good, President and CEO Time: 9:00 AM ET The fireside chat is an invitation-only event and will be available to attending participants.

05:41 29 Sep 2023 TRVI

Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022

Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

02:00 29 Sep 2023 TRVI

How to Find Trending Penny Stocks in 2022

Tips for making a list of trending penny stocks in 2022 The post How to Find Trending Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

TRVI Financial details

Company Rating
Neutral
Market Cap
135.36M
Income
-27.32M
Revenue
0
Book val./share
0.96
Cash/share
0.95
Dividend
-
Dividend %
-
Employees
30
Optionable
No
Shortable
Yes
Earnings
08 Nov 2023
P/E
-8.22
Forward P/E
-
PEG
1.04
P/S
-
P/B
2.36
P/C
2.39
P/FCF
-4.38
Quick Ratio
19.99
Current Ratio
21.06
Debt / Equity
0.02
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.31
EPS next Y
-
EPS next Q
-
EPS this Y
-69.8%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
11.56%
-
-
-
-
SMA20
-3.98%
SMA50
-3.56%
SMA100
-34.24%
Inst Own
49.4%
Inst Trans
1.12%
ROA
-27%
ROE
-26%
ROC
-0.32%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
63.85M
Shs Float
24.68M
-
-
-
-
Target Price
12
52W Range
1.43-3.5
52W High
-24.17%
52W Low
+127.5%
RSI
53.95
Rel Volume
0.13
Avg Volume
176.54K
Volume
22.33K
Perf Week
4.84%
Perf Month
-3.6%
Perf Quarter
26.39%
Perf Half Y
26.39%
-
-
-
-
Beta
0.757735
-
-
Volatility
0.05%, 0.07%
Prev Close
1.56%
Price
2.275
Change
2.94%

TRVI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-2.29-1.46-1.81-1.49-0.45
Operating cash flow per share
-2.04-1.29-1.61-1.27-0.44
Free cash flow per share
-2.06-1.3-1.61-1.27-0.44
Cash per share
1.913.212.491.611.87
Book value per share
1.933.061.510.751.66
Tangible book value per share
1.933.061.510.751.66
Share holders equity per share
1.933.061.510.751.66
Interest debt per share
0.020.020.810.690.15
Market cap
70.74M66.88M43.7M17.87M124.57M
Enterprise value
53.57M9.92M12.91M-4.33M121.15M
P/E ratio
-3.44-2.57-1.33-0.53-4.27
Price to sales ratio
00000
POCF ratio
-3.87-2.9-1.51-0.62-4.42
PFCF ratio
-3.83-2.89-1.51-0.62-4.4
P/B Ratio
4.091.231.61.051.16
PTB ratio
4.091.231.61.051.16
EV to sales
00000
Enterprise value over EBITDA
-2.62-0.37-0.40.13-4.05
EV to operating cash flow
-2.93-0.43-0.450.15-4.3
EV to free cash flow
-2.9-0.43-0.440.15-4.28
Earnings yield
-0.29-0.39-0.75-1.9-0.23
Free cash flow yield
-0.26-0.35-0.66-1.62-0.23
Debt to equity
00.010.520.860.09
Debt to assets
00.010.30.380.07
Net debt to EBITDA
0.842.140.950.680.11
Current ratio
7.0211.458.332.989.15
Interest coverage
-105.790-71.25-27.02-38.34
Income quality
0.890.890.890.850.97
Dividend Yield
00.03000
Payout ratio
0-0.09000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010000.01
Capex to revenue
00000
Capex to depreciation
-6.87-0.23-0.680-3.7
Stock based compensation to revenue
00000
Graham number
9.9810.037.8554.11
ROIC
-1.06-0.48-0.78-1.02-0.26
Return on tangible assets
-1-0.43-0.7-0.88-0.24
Graham Net
1.652.981.430.681.63
Working capital
16.11M54.35M40.71M25.23M109.22M
Tangible asset value
17.31M54.55M27.28M17.08M107.46M
Net current asset value
15.61M54.1M26.42M16.56M107.06M
Invested capital
00.010.520.860.09
Average receivables
122.5K371K411.5K253K120.5K
Average payables
570K1.1M1.81M2.43M2.85M
Average inventory
729.5K1.5M1.25M447.5K0
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1.19-0.48-1.2-1.99-0.27
Capex per share
-0.020000

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
00000
Net income per share
-0.14-0.12-0.06-0.06-0.07
Operating cash flow per share
-0.1-0.12-0.06-0.08-0.1
Free cash flow per share
-0.1-0.12-0.07-0.08-0.1
Cash per share
1.311.821.231.130.95
Book value per share
1.021.61.11.030.96
Tangible book value per share
1.021.61.11.030.96
Share holders equity per share
1.021.61.11.030.96
Interest debt per share
0.210.160.10.090.02
Market cap
167.31M106.1M189.4M182.43M235.89M
Enterprise value
155.14M50.39M185.99M179.79M223.61M
P/E ratio
-5.19-3.21-8.6-7.13-8.25
Price to sales ratio
00000
POCF ratio
-27.09-12.37-29.92-22.26-23.89
PFCF ratio
-27.09-12.37-29.38-22.1-23.79
P/B Ratio
2.760.971.761.792.48
PTB ratio
2.760.971.761.792.48
EV to sales
00000
Enterprise value over EBITDA
-20.09-6.25-27.94-23.77-31.99
EV to operating cash flow
-25.12-5.88-29.38-21.93-22.64
EV to free cash flow
-25.12-5.88-28.85-21.78-22.55
Earnings yield
-0.05-0.08-0.03-0.04-0.03
Free cash flow yield
-0.04-0.08-0.03-0.05-0.04
Debt to equity
0.210.10.090.090.02
Debt to assets
0.150.080.070.080.01
Net debt to EBITDA
1.586.910.510.351.76
Current ratio
5.188.79.158.6521.06
Interest coverage
-40.94-41.4-33.28-43.97-55.51
Income quality
0.771.041.151.281.38
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
000.020.010
Capex to revenue
00000
Capex to depreciation
00-7.73-3-1.18
Stock based compensation to revenue
00000
Graham number
1.762.081.181.231.25
ROIC
-0.11-0.07-0.06-0.07-0.09
Return on tangible assets
-0.1-0.06-0.04-0.06-0.07
Graham Net
0.961.561.070.980.89
Working capital
64.45M112.68M109.22M101M94.5M
Tangible asset value
60.52M109.9M107.46M101.73M95.07M
Net current asset value
58.99M108.86M107.06M99.73M93.31M
Invested capital
0.210.10.090.090.02
Average receivables
00000
Average payables
2.84M3.14M2.6M2.42M1.67M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.13-0.08-0.05-0.06-0.08
Capex per share
00000

TRVI Frequently Asked Questions

What is Trevi Therapeutics, Inc. stock symbol ?

Trevi Therapeutics, Inc. is a US stock , located in New haven of Ct and trading under the symbol TRVI

Is Trevi Therapeutics, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $12. The lowest prediction is $12 and the highest is $12

What is TRVI stock prediction ?

What is Trevi Therapeutics, Inc. stock quote today ?

Trevi Therapeutics, Inc. stock price is $2.275 today.

Is Trevi Therapeutics, Inc. stock public?

Yes, Trevi Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap